Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/14309
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLloyd, J.-
dc.contributor.authorBochner, F.-
dc.date.issued1996-
dc.identifier.citationAustralian Prescriber, 1996; 19(3):79-81-
dc.identifier.issn0312-8008-
dc.identifier.issn1839-3942-
dc.identifier.urihttp://hdl.handle.net/2440/14309-
dc.description.abstractAspirin reduces the risk of non-fatal stroke, non-fatal myocardial infarction and vascular death in patients at high risk of arterial thrombosis. Platelet function is inhibited by doses of 40-160 mg daily. In clinical trials performed before 1985, doses of 500-1500 mg daily were found to be effective. Since 1985, low doses have been evaluated and a meta-analysis has shown that daily doses of 75-150 mg are as effective as the previously used higher doses. The risk of adverse effects is dose-dependent above 75 mg daily. The maximum benefit:risk ratio is likely to be achieved with doses of 75-150 mg daily. In Australia, this is best achieved by either a single 100 mg tablet or half a 300 mg tablet taken daily.-
dc.description.statementofresponsibilityJohn Lloyd, Felix Bochner-
dc.language.isoen-
dc.publisherAustralian Prescriber-
dc.source.urihttp://www.australianprescriber.com/magazine/19/3/79/81/-
dc.subjectformulation-
dc.subjectclinical trials-
dc.subjectadverse effects-
dc.subjectplatelet function-
dc.titleAspirin: How low is low dose?-
dc.typeJournal article-
dc.identifier.doi10.18773/austprescr.1996.070-
pubs.publication-statusPublished-
Appears in Collections:Aurora harvest 2
Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.